Kolexia
Hardy-Bessard Anne-Claire Oncologie médicale
Hardy-Bessard Anne-Claire
Oncologie médicale
Gie Groupement D'imagerie Armoricaine
Plérin, France
173 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Récidive tumorale locale Carcinome épithélial de l'ovaire Hypersensibilité Neutropénie Métastase tumorale

Collaborateurs

Voir plus
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Lortholary Alain
Lortholary Alain
Alek Onco, Nantes, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France

Industries

Voir plus
AstraZeneca
42 collaboration(s)
Dernière en 2023
Novartis
42 collaboration(s)
Dernière en 2023
MSD
37 collaboration(s)
Dernière en 2023
Daiichi Sankyo
21 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   21 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023
MYCA: Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
TAPAZ: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Essai Clinique (Novartis)   05 septembre 2023
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : prise en charge du cancer de l'endomètre localisé.
Bulletin du cancer   14 août 2023